Benzinga | Aug 10, 2021 07:08AM EDT

Fulcrum Therapeutics Q2 EPS $(0.60) Beats $(0.62) Estimate, Sales $4.40M Up From $2.00M YoY

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.62) by 3.23 percent. This is a 9.09 percent increase over losses of $(0.66) per share from the same period last year. The company reported $4.40 million in sales this quarter. This is a 120.00 percent increase over sales of $2.00 million the same period last year.